Skip to main content
Clinical Trials/NCT07182981
NCT07182981RecruitingNot Applicable

Investigating the Relationship Between the Biopsychosocial Status of Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance

Hacettepe University1 site in 1 country50 target enrollmentStarted: August 4, 2025Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
50
Locations
1
Primary Endpoint
Pediatric Eating Assessment Scale (PEDI-EAT-10)

Study Overview

Brief Summary

It is recommended to focus on the physical functionality, chewing, and swallowing performance of individuals diagnosed with scleroderma. There is a need to address children and adults diagnosed with scleroderma comprehensively and to evaluate them on a biopsychosocial basis to support their disease management. The aim was to assess the biopsychosocial characteristics of both children and adults diagnosed with scleroderma and to examine their chewing and swallowing performance.

Additionally, this study aims to identify effective scales that can be used in future research to assess chewing and swallowing in individuals diagnosed with scleroderma.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
7 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Cases diagnosed with scleroderma,
  • Cases aged 7-18 years will be included.

Exclusion Criteria

  • Advanced heart/lung/liver/kidney disease, neurological disease, and malignancies
  • Cases that are not willing to participate in the study will be excluded.
  • Having participated in a regular exercise program for the past 3 months
  • Individuals who are not willing to participate in the study
  • For adults diagnosed with scleroderma:
  • Inclusion Criteria:
  • Individuals diagnosed with scleroderma,
  • Individuals over the age of 18 will be included.
  • Exclusion Criteria:
  • Advanced heart/lung/liver/kidney disease, neurological disease, and malignancies
  • Individuals who are not willing to participate in the study will be excluded.
  • Having participated in a regular exercise program for the past 3 months
  • Individuals who are not willing to participate in the study

Outcomes

Primary Outcomes

Pediatric Eating Assessment Scale (PEDI-EAT-10)

Time Frame: Two weeks

It is used to evaluate swallowing disorders in pediatric patients. It was developed as the pediatric version of the EAT-10, which is used in adults. The PEDI-EAT-10 comprises 10 questions, each with a Likert scale ranging from 0 to 4 (0 = no problem, 4 = severe problem). The total score is calculated out of 40 points.

Chewing and Swallowing Test for Children (TOMASS-C)

Time Frame: Two weeks

It is a measurement tool developed specifically for children to assess chewing performance. TOMASS-C is a standardized method that quantitatively evaluates the chewing and swallowing of a solid food (cracker) in the pediatric population. During the test, the following parameters will be observed and recorded: * Number of bites * Number of chewing cycles * Number of swallows * Task completion time (in seconds)

3-Ounce Water Swallow Challenge

Time Frame: Two weeks

It is a commonly used method for assessing oropharyngeal dysphagia and aspiration risk. Subjects must swallow 3 ounces (90 cc) of water without interruption. Failure to complete the task, coughing, choking, or exhibiting a wet-gurgling voice quality within 1 minute during or after the test is included. Subjects who can drink 90 cc of water completely and in one go without coughing, choking, or drinking the water in portions have completed the test.

Turkish Eating Assessment Tool (T-EAT-10)

Time Frame: Two weeks

It is a questionnaire consisting of 10 questions with a Likert scale ranging from 0 to 4 (0 = no problem, 4 = severe problem). The total score is calculated out of 40 points by summing the responses given to each question. A score of 3 or higher is considered abnormal in the questionnaire.

Test of Masticating and Swallowing Solids (TOMASS)

Time Frame: Two weeks

The test evaluates how many bites it takes an individual to eat a biscuit while sitting upright, how many chewing cycles they perform, how many times they swallow, and the total time from bite to swallow. The number of bites, number of chewing cycles, number of swallows, and total time will be calculated.

Maximum Mouth Opening (MMO)

Time Frame: Two weeks

After ensuring that individuals open their mouths as wide as possible, the distance between the incisal edges of the central incisors in the upper and lower jaws will be measured in millimeters using a ruler, and the values will be recorded.

Dysphagia Limit (DL)

Time Frame: Two weeks

Individuals are given liquids in volumes of 5, 10, 15, 20, 25, 30, 35, 40, and 45 mL using a graduated syringe, and they are asked to swallow the liquid. The maximum amount of liquid that can be swallowed during a single movement of the thyroid cartilage is determined. In healthy individuals, the normal dysphagia limit is more than 20 mL. If a person can normally swallow 20 mL, the dysphagia limit is considered normal.

Secondary Outcomes

  • Juvenile Arthritis Biopsychosocial Scale-JAB-Q-Family(Two weeks)
  • Juvenile Arthritis Biopsychosocial Scale-JAB-Q-Patient(Two weeks)
  • Childhood Health Assessment Questionnaire (CHAQ)(Two weeks)
  • Mouth Handicap in Systemic Sclerosis Questionnaire (MHIIS)(Two weeks)
  • Modified Hand Mobility in Scleroderma Test (mHAMIS)(Two weeks)
  • Juvenile Arthritis Quality of Life Questionnaire (JAQQ)(Two weeks)
  • Modified Rodnan skin score (MRSS)(Two weeks)
  • Localized Scleroderma Assessment Tool (LoSCAT)(Two weeks)
  • Fonseca Anamnestic Questionnaire(Two weeks)
  • Child and Adolescent Scale of Participation (CASP)(Two weeks)
  • Cognitive Exercise Therapy Approach-Biopsychosocial Questionnaire (BETY-BQ)(Two weeks)
  • Short Form-36 (SF-36)(Two weeks)
  • Scleroderma Health Assessment Questionnaire (SHAQ)(Two weeks)
  • Hospital Anxiety and Depression Scale (HADS)(Two weeks)
  • Pain Catastrophizing Scale-Parent (PCS-P)(Two weeks)
  • Central Sensitization Scale (CSS)(Two weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Orkun Tüfekçi

Principal Investigator, PT, PhD(c)

Hacettepe University

Study Sites (1)

Loading locations...

Similar Trials

Patients Diagnosed With Scleroderma and... | Clinical Trial